Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 03 January, 2006

XTL Biopharm Ltd

Appointment of Ron Bentsur as CEO


XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive 
                                    Officer                                    

Rehovot, Israel; Tuesday, 3 January 2006 - XTL Biopharmaceuticals, Ltd.
('XTLbio') (LSE: XTL; NASDAQ: XTLB; TASE: XTL), a biopharmaceutical company
developing drugs against hepatitis, announced today the appointment of Ron
Bentsur as Chief Executive Officer of the Company. Ron Bentsur is based in the
US.

Michael S. Weiss, Chairman of XTLbio's Board of Directors, stated, 'On behalf
of the Board, I want to welcome Ron Bentsur to XTLbio. Ron is an experienced
biotechnology executive with a track record for assisting in creating
shareholder value. I believe that Ron's excellent and longstanding
relationships with the biotechnology investment, research and banking
communities in the US and Europe will be a true asset to the Company. I am
confident that under Ron's dedicated leadership, XTLbio will continue along its
trajectory towards success and become a major player in the biotechnology
sector.'

'I am extremely excited about this opportunity,' said Mr. Bentsur. 'I look
forward to working with the XTLbio management team to continue to build
long-term value in the Company. I am eager to begin to leverage our
capabilities to position the Company for long-term success.'

Ron Bentsur has nearly a decade of experience in the biotech industry. Most
recently, Mr. Bentsur served as Vice President, Finance and Investor Relations
of Keryx Biopharmaceuticals, a position he has held since June 2003. From
October 2000 to June 2003, Mr. Bentsur served as Director of Investor Relations
at Keryx. From July 1998 to October 2000, he served as Director of Technology
Investment Banking at Leumi Underwriters, where he was responsible for all
technology/ biotechnology private placement and advisory transactions. From
June 1994 to July 1998, Mr. Bentsur worked as an investment banker at ING
Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business
Administration with distinction from the Hebrew University of Jerusalem, Israel
and an MBA, Magna Cum Laude, from New York University's Stern Graduate School
of Business.

During an interim transitional period, Mr. Bentsur will continue to serve as
Vice President, Finance and Investor Relations of Keryx Biopharmaceuticals,
Inc.

Contact XTLbio:

Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

About XTLbio

XTL Biopharmaceuticals Ltd ('XTLbio') is engaged in the research, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a particular focus on hepatitis C. XTLbio's most advanced therapeutic in
Hepatitis C is XTL-6865 - a combination of two monoclonal antibodies against
the hepatitis C virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTLbio's second Hepatitis C therapeutic is XTL-2125 - a
small molecule inhibitor of the hepatitis C Virus polymerase - expected to
enter Phase 1 clinical trials in 1H2006. XTLbio hepatitis C pipeline also
includes several families of pre-clinical hepatitis C small molecule
inhibitors. In 2004, XTLbio licensed HepeX-B - an antibody therapeutic against
hepatitis B - to Cubist Pharmaceuticals. XTLbio is publicly traded on the
London, NASDAQ, and Tel-Aviv Stock Exchanges (LSE: XTL; NASDAQ: XTLB; TASE:
XTL).



                                                                                                                                                                                                

a d v e r t i s e m e n t